Warren Buffett and Charlie Munger are the two investment heads of Berkshire Hathaway. If they decide to put money into a business, they usually have a good nose for their investment, which will pay off.
With a long-term annual return wide above 20 percent, they definitely have done most things right.
Today I would like to present you the best dividend stocks from the GuruFocus Buffett-Munger screener. The tool searches the market for good companies at fair or even undervalued prices. The screener take only stocks with a high predicable business into account.
These are some of the criteria:
- Rising margin.
- Growing business.
- Little debt.
- Fair or undervalued.
The Buffett-Munger screener gives you over 200 results, but I like to focus on the U.S. stock market.
From 77 American stocks, only 15 shares pay dividends. Buffett and Munger would definitely love some of these results.
Hot Media Companies For 2015: Lean Hogs (HE)
Hawaiian Electric Industries, Inc., through its subsidiaries, primarily engages in electric utility and banking businesses primarily in Hawaii. The company is involved in the production, purchase, transmission, distribution, and sale of electricity from renewable energy sources, such as wind, solar, photovoltaic, geothermal, wave, hydroelectric, sugarcane waste, municipal waste, and other biofuels, as well as from fuel oil. It distributes and sells electricity on the islands of Oahu, Hawaii, Maui, Lanai, and Molokai; and serves suburban communities, resorts, the United States armed forces installations, and agricultural operations. As of December 31, 2011, the company had net generating and firm purchased capability of 2,326.9 megawatts. It also engages in providing banking and other financial services, such as accepting savings accounts, checking accounts, money market accounts, and certificates of deposit; and providing loans comprising residential and commercial real es tate, residential mortgage, construction and development, multifamily residential and commercial real estate, consumer, and commercial loans to consumers and business. The company operated 57 branches and 119 automated teller machines. Hawaiian Electric Industries, Inc. was founded in 1891 and is based in Honolulu, Hawaii.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Utilities stocks gained Friday, with Korea Electric Power (NYSE: KEP) leading advancers. Meanwhile, gainers in the sector included Huaneng Power International (NYSE: HNP), with shares up 1.8 percent, and Hawaiian Electric Industries (NYSE: HE), with shares up 1.4 percent. - [By Jake L'Ecuyer]
Utilities shares dropped by 0.31 percent in the US market today. Among the sector stocks, Hawaiian Electric Industries (NYSE: HE) was down more than 2.9 percent, while Edison International (NYSE: EIX) tumbled around 1.4 percent.
5 Best Warren Buffett Stocks To Invest In 2014: Industrias CH SAB de CV (ICHB)
Industrias CH SAB de CV (ICH) is a Mexico-based holding company engaged, together with its subsidiaries, in the steel industry. The Company's activities include the production, processing and distribution of special bar quality (SBQ) steel products; coated and uncoated seamed pipes; structural steel products, such as beams, channels, flat bars and angles; light structurals, such as angles, flat and merchant bars; as well as reinforced and corrugated steel bars. The Company�� facilities include production and processing plants in Mexico, the United States and Canada. Advisors' Opinion:- [By Julia Leite]
The IPC rose 2.5 percent to 40,623.30 at the close in Mexico City. The index gained 6.8 percent on the week, the most since July 2009. Steelmaker Industrias CH SAB (ICHB) was the biggest gainer today, while homebuilders Desarrolladora Homex SAB, Urbi Desarrollos Urbanos SAB, and Corp. Geo SAB were the week�� best performers.
5 Best Warren Buffett Stocks To Invest In 2014: Myriad Genetics Inc (MYGN)
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).
As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.
Molecular Diagnostic Tests
The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence and measure a patient's exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.
The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.
The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.
Companion Diagnostic Services and Other Revenue
! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.
The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.
Advisors' Opinion:- [By James E. Brumley]
Earlier this week, Roche Holding Ltd. (OTCMKTS:RHHBY) made big news by winning the FDA's approval to administer a breast cancer drug before surgical removal of a breast tumor ... the first time the Food and Drug Administration has believed surgery (then followed by drugs and chemo) wasn't the best approach. Earlier in the year, a company called Myriad Genetics, Inc. (NASDAQ:MYGN) made a big splash, helped along by celebrity Angelina Jolie, who - using a DNA test from the genetic-testing company - elected to undergo a double mastectomy because her diagnostic's scores she was at a greater risk of breast cancer. Aside from being good for MYGN and RHHBY shareholders, both Roche Holding and Myriad Genetics are doing good work for cancer patients (and pre-cancer patient) too. Yet, there's another smaller company close to entering the same breast cancer fight that made big news of its own today... MetaStat Inc. (OTCMKTS:MTST). Indeed, this off-the-radar company in many ways has more potential than Myriad or Roche do, just by the virtue and capability of its underlying science.
5 Best Warren Buffett Stocks To Invest In 2014: Whitecap Resources Inc (SPGYF.PK)
Whitecap Resources Inc., formerly Spitfire Energy Ltd., is engaged in the exploration, development and production of crude oil, natural gas and natural gas liquids in Western Canada. The Company�� activities are concentrated primarily in Northwest Central Alberta and Southwest Saskatchewan. On July 1, 2010, the Company amalgamated with its wholly owned subsidiary Whitecap Resources Inc. During fiscal 2010, the Company produced an average of 355 barrels of oil equivalent per day (boed). On July 12, 2010, the Company entered into an agreement to acquire a private company. The primary assets to be acquired are located in the Pembina region of west central Alberta with production and reserves focused in the Cardium formation. In October 2013, the Company announced that it has completed the acquisition of a Cardium light oil property and a working interest consolidation of its Eagle Lake Viking unit. Advisors' Opinion:- [By Caiman Valores]
The recent surge in oil prices has renewed investor interest in the small-cap oil and gas E&P sector. One company that stands out for all the right reasons is Canadian domiciled small-cap, Whitecap Resources (SPGYF.PK). Since 2009 the company has unlocked considerable value for investors through a range of acquisitions as well as development and exploration projects. This has seen its share price surge in value to be up by almost 53% over the last year alone. However, it is clear that the market has yet to fully recognize the true value of Whitecap and there is still considerable upside potential of over 30% for investors. This along with Whitecap's dividend growth strategy makes it a particularly appealing deep-value investment in the oil and gas E&P sector.
No comments:
Post a Comment